drugset / Trial / NCT02189109
The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma
NaSingle-groupOpen-labelTreatment
Summary
This clinical trial is testing the safety, tolerability and effectiveness of NVX-108 administered via intravenous infusion in combination with standard radiation and chemotherapy. NVX-108 is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.
Timeline
- Start
- 2014-05
- Primary completion
- 2017-08-31
- Completion
- 2018-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PERFLENAPENT | Small molecule | 0.05 ml | Intravenous |
| Subject | PERFLENAPENT | Small molecule | 0.1 ml | Intravenous |
| Subject | PERFLENAPENT | Small molecule | 0.17 ml | Intravenous |